Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer

NCT05638594 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

236

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Pyrotinib
DRUG: Trastuzumab
DRUG: Dalpiciclib
DRUG: Letrozole
DRUG: Pertuzumab
DRUG: Docetaxel
DRUG: Carboplatin
DRUG: Gonadotropin-releasing hormone agonist

Sponsor

Shengjing Hospital